Mitigating Cross-Contamination in Shared Production Facilities Using Risk-Based Cleaning Validation Methods

In 1984, Harder published an article, "The Validation of Cleaning Procedures," which introduced key concepts for establishing a cleaning limit. This limit must be practical and achievable by a reasonable cleaning procedure and verifiable by analytical methodology. The article referenced 21 Code of Federal Register §193, "Tolerances for Pesticides in Food Administered by the Environmental Protection Agency," and included a table of limits for various substances. Regulatory guidance for cleaning validation has also evolved over time. The European Medicines Agency (EMA) has published questions and answers on cleaning validation, which provide guidance on the requirements for cleaning validation in the European Union. The EMA emphasizes the importance of risk assessment in cleaning validation, as well as the need for a cleaning validation protocol that is tailored to the specific product and equipment being used. A risk-based approach to cleaning validation involves identifying the potential risks of cross-contamination and implementing measures to mitigate those risks. This approach is becoming increasingly important in the pharmaceutical industry, as regulatory agencies place greater emphasis on the need for robust cleaning validation protocols. In a shared manufacturing facility, the risk of cross-contamination is particularly high, as multiple products are being manufactured in the same equipment train. One example of a risk-based approach to cleaning validation is the use of a CV matrix to select the worst-case product. This involves identifying the product that is most likely to be contaminated and developing a cleaning validation protocol that is tailored to that product. The CV matrix can also be used to identify the cleaning method that is most effective for the worst-case product. In addition to the CV matrix, other factors must be considered when developing a cleaning validation protocol. These include the cleaning limit, which must be practical and achievable by a reasonable cleaning procedure, and the analytical methodology used to verify the cleaning limit. The cleaning limit must be set at a level that is low enough to ensure that the product is not contaminated, but high enough to be practical and achievable. A case study on the prevention of cross-contamination of cyclosporine into an anti-tuberculosis (TB) medicine in a shared manufacturing facility provides a practical example of how a risk-based approach to cleaning validation can be implemented. The case study involves a risk assessment and mitigation of potential cyclosporine cross-contamination, as well as a cleaning validation protocol that is tailored to the worst-case product. The cleaning validation protocol for cyclosporine involves a limit of cleaning evaluation, which is used to determine the effectiveness of the cleaning procedure. The protocol also involves a risk assessment and mitigation of potential cyclosporine cross-contamination, which is used to identify the potential risks of cross-contamination and implement measures to mitigate those risks. In conclusion, the evolution of cleaning validation in the pharmaceutical industry has been driven by regulatory requirements and industry advances. A risk-based approach to cleaning validation involves identifying the potential risks of cross-contamination and implementing measures to mitigate those risks. This approach is becoming increasingly important in the pharmaceutical industry, as regulatory agencies place greater emphasis on the need for robust cleaning validation protocols.